Literature DB >> 15609302

Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database.

André Lopes Carvalho1, Inês Nobuko Nishimoto, Joseph A Califano, Luiz Paulo Kowalski.   

Abstract

Despite recent advances in the diagnosis and treatment of head and neck cancer, there has been little evidence of improvement in 5-year survival rates over the last few decades. To determine more accurate trends in site-specific outcomes as opposed to a more general overview of head and neck cancer patients, we analyzed the site-specific data collected in the Surveillance, Epidemiology, and End Results-SEER Public-Use Database 1973-1999. Based on the selection criteria, 96,232 cases were evaluated for trend analysis in incidence, clinical stage, treatment and 5-year survival. During the period 1973-1999, site-specific incidence rates for head and neck cancer changed significantly. Site-specific analysis of survival from 1974-1997 showed significant improvements in 5-year survival rates for cancers of the nasopharynx, oropharynx and hypopharynx (38.1% to 56.7% for nasopharynx, p < 0.001; 36.3% to 49.1% for oropharynx, p = 0.001 and 28.3% to 33.3% for hypopharynx, p = 0.015). The prognosis for early-stage salivary gland cancer during 1983-1997 and late-stage larynx cancer during 1974-1997 also demonstrated improvement (82.7% to 88.5%, p = 0.012 and 22.2% to 38.3%, p = 0.013, respectively). On the other hand, the prognosis for regional stage oral cavity cancer as well as early-stage larynx cancer patients declined during 1983-1997 (49.2% to 43.8%, p = 0.032 and 82.3% to 74.3%, p = 0.002, respectively). Site-specific changes in treatment and staging were also noted. Site-specific analysis allows for a more accurate description of incidence, staging, treatment, and prognostic trends for head and neck cancer. 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15609302     DOI: 10.1002/ijc.20740

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  250 in total

1.  EIF2C is overexpressed and amplified in head and neck squamous cell carcinoma.

Authors:  Steven S Chang; Ian Smith; Chad Glazer; Patrick Hennessey; Joseph A Califano
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2010-10-01       Impact factor: 1.538

Review 2.  The biology of head and neck cancer stem cells.

Authors:  Zhaocheng Zhang; Manoel Sant'Ana Filho; Jacques E Nör
Journal:  Oral Oncol       Date:  2011-11-08       Impact factor: 5.337

3.  Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: an epigenome-wide association study.

Authors:  Scott M Langevin; Devin C Koestler; Brock C Christensen; Rondi A Butler; John K Wiencke; Heather H Nelson; E Andres Houseman; Carmen J Marsit; Karl T Kelsey
Journal:  Epigenetics       Date:  2012-03       Impact factor: 4.528

4.  Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer.

Authors:  Wei Yang; Quan Cai; Vivian W Y Lui; Patrick A Everley; Jayoung Kim; Neil Bhola; Kelly M Quesnelle; Bruce R Zetter; Hanno Steen; Michael R Freeman; Jennifer R Grandis
Journal:  J Proteome Res       Date:  2010-06-04       Impact factor: 4.466

5.  Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma.

Authors:  Samantha J Davis; Vasu Divi; John H Owen; Carol R Bradford; Thomas E Carey; Silvana Papagerakis; Mark E P Prince
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-12

6.  Clusterin is a gene-specific target of microRNA-21 in head and neck squamous cell carcinoma.

Authors:  Wojciech Mydlarz; Mamoru Uemura; Sun Ahn; Patrick Hennessey; Steven Chang; Semra Demokan; Wenyue Sun; Chunbo Shao; Justin Bishop; Julie Krosting; Elizabeth Mambo; William Westra; Patrick Ha; David Sidransky; Joseph Califano
Journal:  Clin Cancer Res       Date:  2013-12-10       Impact factor: 12.531

7.  Aspirin use and head and neck cancer survival: an observational study of 11,623 person-years follow-up.

Authors:  Shin-Ae Kim; Jong-Lyel Roh; Sung-Bae Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Int J Clin Oncol       Date:  2017-07-19       Impact factor: 3.402

8.  The histologic risk model is a useful and inexpensive tool to assess risk of recurrence and death in stage I or II squamous cell carcinoma of tongue and floor of mouth.

Authors:  Namita Sinha; Matthew H Rigby; Michael L McNeil; S Mark Taylor; Jonathan Rb Trites; Robert D Hart; Martin J Bullock
Journal:  Mod Pathol       Date:  2018-02-02       Impact factor: 7.842

Review 9.  Recent Landmark Studies on Head and Neck Cancers: Evidence-Based Fundamentals of Modern Therapeutic Approaches.

Authors:  Utku Aydil
Journal:  Turk Arch Otorhinolaryngol       Date:  2015-03-01

10.  Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.

Authors:  Wanglong Qiu; Guo-Xia Tong; Spiros Manolidis; Lanny G Close; Adel M Assaad; Gloria H Su
Journal:  Int J Cancer       Date:  2008-03-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.